TRIAL STATUS: ENROLLING
Phase III Study
ARENA-2: A study evaluating the continued safety and efficacy of ADV7103 in subjects with primary distal renal tubular acidosis (dRTA).
Patient and Family Resources
About primary dRTA
Primary, or hereditary, distal renal tubular acidosis is a rare kidney disorder that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood—a condition called acidosis—which leads to a metabolic imbalance. dRTA is a serious disorder, especially for pediatric patients.
Early signs and symptoms in babies include nausea and vomiting, dehydration, extreme tiredness, feeding issues and problems with weight gain. Children can also develop rickets, and often experience stunting of growth.
Mineral imbalances caused by dRTA can lead to kidney stones and hypokalemia, or decreased levels of potassium in the blood. Hypokalemia causes severe muscle weakness, shortness of breath and abnormal heart rhythm.
dRTA can cause digestive disorders, such as anorexia, vomiting, diarrhea, and constipation, and can also lead to hearing loss.
About the ARENA-2 clinical trial
Advicenne has completed a Phase III trial in Europe (clinical studies B21CS and B22CS).
We are currently recruiting participants for a US Phase III trial. For information about this clinical trial, please visit its listing on the NIH clinical trials database here.